Sales of medical aesthetics such as Botulinum toxin type A (Botox) were expected to be heavily impacted by the pandemic as patients were discouraged against elective and cosmetic medical procedures. As a result, a pharma company’s innovation team needed to identify non-aesthetic applications for Botox that would allow them to quickly address the reduction in market demand.
By reviewing their recently acquired partner’s patent portfolio, as well as using ResoluteAI's forward citation analysis, the company was able to identify new applications for their existing products.
ResoluteAI's research-engine empowered their innovation team to make connections across multiple therapeutic areas, leading them to shift their marketing from aesthetics to migraine treatment. As a result, the company was able to improve their expected sales forecast for FY21 and surprised many with Botox's resilience during the pandemic.